61367-16-6

Usage

Chemical Properties

White crystalline powder

Uses

Methyl cis-4-aminocyclohexanecarboxylate HCl

InChI:InChI:1S/C8H15NO2.ClH/c1-11-8(10)6-2-4-7(9)5-3-6;/h6-7H,2-5,9H2,1H3;1

Upstream product

• 67-56-1 methanol 
• 1776-53-0 trans-4-aminocyclohexanecarboxylic acid 
• 146307-51-9 methyl (1R,4R)-4-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylate 
• 3685-23-2 cis-4-aminocyclohexane-1-carboxylic acid 
• 150-13-0 4-amino-benzoic acid 

Downstream Products

• 364385-64-8 cis-4-(tert-butoxycarbonylamino)cyclohexanecarboxylic acid methyl ester 
• 727736-49-4 methyl trans-4-[(3-hydroxypropanoyl)amino]cyclohexanecarboxylate 
• 727736-96-1 methyl trans-4-({2-[(t-butoxycarbonyl)amino]ethyl}amino)-cyclohexanecarboxylate 
• 609805-47-2 methyl trans-4-(morpholin-4-yl)cyclohexanecarboxylate 
• 727737-07-7 methyl (1r,4r)-4-(dimethylcarbamoyl)cyclohexane-1-carboxylate 
• 727736-47-2 methyl trans-4-(glycoloylamino)cyclohexanecarboxylate 
• 609805-37-0 methyl trans-4-[(4-chlorobutanoyl)amino]cyclohexanecarboxylate 
• 609805-64-3 methyl trans-4-({[2-(2-benzyloxy)ethoxy]acetyl}amino)cyclohexanecarboxylate 
• 609805-45-0 methyl trans-4-(pyrrolidin-1-yl)cyclohexanecarboxylate 
• 150594-70-0 6-(4-Cyanophenyl)-4-[[trans-4-(methoxycarbonyl)-cyclohexyl]-aminocarbonyl]-2-[(morpholinocarbonyl)-methyl]-(2H)-pyridazin-3-one 
• 167756-97-0 5-tert-butyloxycarbonyl-2-[4-[(trans-4-methoxycarbonyl-cyclohexyl)-aminocarbonyl]-phenyl]-4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridine 
• 733784-92-4 methyl trans-4-(1-piperidyl)cyclohexanecarboxylate 
• 1207529-63-2 trans-4-(2-chloro-5-trifluoromethyl-benzoylamino)-cyclohexane carboxylic acid methyl ester 
• 1319743-48-0 trans-methanesulfonic acid 4-(2-chloro-5-trifluoromethyl-benzoylamino)-cyclohexyl methyl ester 

Relevant academic research and scientific papers

SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS

Compounds of Formula (I) and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

NITROGENOUS FUSED BICYCLIC COMPOUND

A novel nitrogenous fused bicyclic compound represented by the following general formula [1] or a pharmacologically acceptable salt of the compound. They have excellent SK channel blocking activity and are useful as a medicine. [I] (In the formula, R 0 represents hydrogen, halogeno, etc.; R 1 represents a group represented by the formula (a) or (b); A represents a group represented by the formula (X) or (Y); D 1 , D 2 and D 3 each represents N or CH; R 2 represents halogeno or optionally halogenated lower alkyl, etc.; R 3 represents hydrogen or lower alkyl; and Q represents lower alkylene.)

FUSED FURAN COMPOUND

The present invention provides a condensed furan compound of the formula (I): wherein Ring X is benzene, pyridine, or the like; Y is an optionally substituted amino, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted saturated heterocyclic group, an optionally substituted unsaturated heterocyclic group; A is a single bond, lower alkylene, lower alkenylidene, lower alkenylene or an oxygen atom; R3 is hydrogen or the like; and , R4 is hydrogen, or the like, or pharmaceutically acceptable salts thereof, which is useful as a medicament, particularly, as an activated blood coagulation factor X inhibitor.

Heterocycle derivatives and drugs

There is provided an excellent novel analgesic having an analgesic effect which is effective widely against a pain including a chronic pain or an allodynia accompanied with herpes zoster by acting on a nociceptin receptor. The present invention relates to a compound represented by the following formula: or a salt thereof. In the formula, X and Y are same or different and each represents a nitrogen atom or CH; R1 represents a hydrogen atom or alkyl and the like; A1 and A2 are same or different and each represents a single bond or a divalent aliphatic hydrocarbon group; Q represents a single bond, cycloalkylene group, phenylene group or divalent heterocyclic group; R2A, R2B, R2C and R2D are same or different and each represents a hydrogen atom, alkyl or phenyl; E represents a ethenylene group or —NRCO— (in which R is hydrogen or alkyl) and the like; R3 represents a phenyl group or a heterocyclic group; R4 and R5 are same or different and each represents a hydrogen atom, alkyl, alkoxy, aralkyloxy, halogen, nitro, hydroxy, alkoxycarbonyl, —NR6R7 (in which R6 and R7 are same or different and each represents a hydrogen atom or alkyl) and the like.

Streptogramin derivatives, their preparation and compositions containing them

Group A streptogramin derivatives of general formula (I) in which:R1 represents a halogen atom or an azido or thiocyanato radical,R2 represents a hydrogen atom or a methyl or ethyl radical,R3 represents a hydrogen atom, or the residue of an aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic or heterocyclylaliphatic ester which may be substituted, andthe bond - - -represents a single bond (stereochemistry 27R) or a double bond,as well as its salts when they exist.

Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase

Compounds of formula (I) STR1where R 1 is hydrogen; R 2 is nitro, cyano or halo(lower)alkyl; R 3 is phenyl substituted with one or more substituents selected from halogen, cyano and lower alkoxy; A is a lower alkylene group; R 4 is a group CR 6 R 7 R 8 wherein R 6 and R 7 form, together with the carbon atom to which they are attached a cycloalkyl group optionally substituted with hydroxy, lower alkoxy or a lower alkanoylamino; and R 8 is hydrogen; its prodrug and a salt thereof.

Approaches towards the synthesis of fluoro(cyclo)alkylamines

The synthesis of fluoro(cyclo)alkylamines 1-amino-6-fluorohexane (1), 1-amino-7-fluoroheptane (2), cis/trans-4-fluorocyclohexylamine (3a,b) and cis-4-fluoromethylcyclohexylamine (4) has been investigated for use as synthons for histamine receptor ligands for use in PET.

Aminobenzoic and aminocyclohexanecarboylic acid compounds, compositions, and their method of use

Compounds of the formula inhibit the action of neutral endopeptidase. As a result, such compounds produce diuresis, natriuresis, and lower blood pressure as well as being useful in the treatment of congestive heart failure, relieving pain, and diarrhea when administered to a mammalian host.

Synthesis of analogues of N (2 chloroethyl) N' trans 4 methylcyclohexyl) N nitrosourea for evaluation as anticancer agents

The superior activity of N (2 chloroethyl) N' (trans 4 methylcyclohexyl) N nitrosourea (MeCCNU) against advanced murine Lewis lung carcinoma in comparisons with the cis form and other nitrosoureas prompted the synthesis of a number of MeCCNU analogues, including several cis trans pairs. The methyl group was replaced by a variety of substituents (CO2H, CH2CO2H, CO2Me, CH2OAc, CH2Cl, OMe); the trans 3 methylcyclohexyl, cis 2 methyl 1,3 dithian 5 yl, cis and trans 2 methyl 1,3 dithian 5 yl tetraoxide, and 1 methylhexyl (open chain) analogues were also prepared. Preliminary tests against murine leukemia L1210 revealed therapeutic indices (ED50/LD10) ranging from 0.26 to 0.79; all but 3 analogues effected 50% cure rates at nontoxic doses, the open chain analogue being one of the least active. In terms of therapeutic index, diequatorial (trans 4) isomers were, with one exception, as active as or, in 4 of the 8 examples, somewhat more active than the corresponding axial equatorial (cis 4) isomers. In this series, 4 of the 5 2-fluoroethyl analogues prepared were clearly inferior to the corresponding 2 chloroethyl analogues.